Abstract: A method disclosed herein includes operating a processor of a system on a chip in a configuration mode until completion of a set of tasks, and operating the processor in a normal operation mode after completion of the set of tasks. During the configuration mode, the method includes performing steps of sending by the processor of configuration information to a configuration programming block, sending by the configuration programming block of the configuration information to one or more electronic components to thereby complete a first subset of the set of tasks, while permitting the processor to complete a second subset of the set of tasks, and sending by the configuration programming block of a notification to the processor after completing the first subset of the set of tasks.
Abstract: The present invention relates to LpxC antibacterial compounds of Formula (IA): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.
Type:
Application
Filed:
December 8, 2016
Publication date:
December 20, 2018
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Qi JIN, Denise Teotico POHLHAUS, Jared T. SPLETSTOSER
Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.
Type:
Grant
Filed:
September 22, 2015
Date of Patent:
December 4, 2018
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Niall Andrew Anderson, Ian Baxter Campbell, Matthew Howard James Campbell-Crawford, Ashley Paul Hancock, Seble Lemma, Simon John Fawcett MacDonald, John Martin Pritchard, Panayiotis Alexandrou Procopiou
Abstract: A diffractive optical element (DOE) is designed to implement both a collimation function with respect to an input divergent beam and a beam shaping function with respect to an output divergent beam. The phase designs of the collimation function and the beam shaping function are independently produced in the phase domain. These phase designs are then combined using a phase angle addition of the individual functions and wrapped between 0 and 2? radians. The diffractive surface of the DOE is then defined from the wrapped phase angle addition of the individual functions.
Abstract: The present invention provides a method for treating or ameliorating cerebrovascular diseases in a subject by using peptides isolated from extracts from rabbit skin inflamed by vaccinia virus. The present invention also provides a peptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 1, or variants, mutants, derivatives, or fragments thereof.
Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
November 13, 2018
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
Abstract: An electronic device includes at least one photodetection block, where the at least one photodetection block includes a plurality of macropixels arranged into an array. Each macropixel includes an array of photodiodes, with logic circuitry coupled to outputs of the array of photodiodes and configured to generate a detection signal as a function of logically combining the outputs of the array of photodiodes. Each macropixel has associated therewith selection circuitry configured to selectively pass the detection signal to output combining logic or to output combining logic of at least one neighboring macropixel of the plurality thereof. The output combining logic has inputs coupled to the selection circuitry and to the selection circuitry of the at least one neighboring macropixel, and is configured to generate an output detection signal as a function of logically combining outputs of the selection circuitry and the selection circuitry of the at least one neighboring macropixel.
Abstract: Photoluminescence from a sample detector is detected using an array of photo-sensitive detectors. At least one first photo-sensitive detector of the array is provided with a first type of linear polarization filter and at least one second photo-sensitive detector is provided with a second type of linear polarization filter. The first type of linear polarization filter has a plane of polarization which is at angled with respect to a plane of polarization of said second type of polarization filter.
Abstract: An apparatus includes a camera module configured to generate at least one image and a ToF SPAD based range detecting module configured to generate at least one distance determination to an object within a field of view of the camera module. A processor receives the at least one image from the camera module output and receives the at least one distance determination from the ToF SPAD based range detecting module. This data is processed by the processor to determine a depth map.
Abstract: An electronic device disclosed herein includes a first integrated circuit die having formed therein photodiodes and readout circuitry for the photodiodes, with the readout circuitry including output pads exposed on a surface of the first integrated circuit die. A second integrated circuit die has formed therein storage capacitor structures for the photodiodes and digital circuitry for performing image processing on data stored in the storage capacitor structures, with the storage capacitor structures including input pads exposed on a surface of the second integrated circuit die. The first and second integrated circuit die are in a face to face arrangement such that the output pads of the first integrated circuit die face the input pads of the second integrated circuit die. An interconnect couples the output pads of the first integrated circuit die to the input pads of the second integrated circuit die.
Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
Type:
Grant
Filed:
January 23, 2018
Date of Patent:
October 30, 2018
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: A seal formulation for forming a physical barrier in the teat canal of a non-human animal for prophylactically controlling infection of a mammary gland by a mastitis-causing organism comprises a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof. The lower alkyl vinyl ether-maleic anhydride copolymer salt derivative may comprise at least one cationic ion including monovalent, bivalent or trivalent cations and mixtures thereof.
Type:
Application
Filed:
October 19, 2016
Publication date:
October 25, 2018
Applicant:
Bimeda Research & Development Limited
Inventors:
Francisco Javier MOLINS ALBANELL, Brendan Gerard SMITH, James KENNEDY, Fiona NÍ CHEARÚIL
Abstract: A system, method, and computer program product are provided for media content playback management. In operation, a profile system receives media information and current playback information associated with media content being played on a first device including a first streaming software agent capable of monitoring media data traffic from a plurality of different streaming media sources and a first local buffer for buffering the media content. The profile system identifies a profile associated with a user of the first device. The profile system stores the media information and the current playback information in association with the profile associated with the user of the first device. The profile system receives a request to play the media content on a second device including a second streaming software agent capable of monitoring the media data traffic from the plurality of different streaming media sources and a second local buffer for buffering the media content.
Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
Type:
Grant
Filed:
May 27, 2015
Date of Patent:
October 23, 2018
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: A system, method, and computer program product are provided for proactively identifying and addressing customer needs. In use, at least one customer need for at least one customer is predicted, based, at least in part, on information associated with the one or more detected customer care request triggering events, information associated with the one or more customer care interactions, and information associated with the one or more after-effects.
Type:
Grant
Filed:
March 22, 2016
Date of Patent:
October 9, 2018
Assignee:
Amdocs Development Limited
Inventors:
Craig Dean Hanson, Joseph Patrick O'Hara, Shanmugam Chinnappa Gounder
Abstract: Systems and methods may replace and/or enhance green screens. A green screen may be replaced and/or enhanced by receiving green screen data, determining a modification to be applied to the green screen data, generating a user interface screen including the green screen data and the modification, and causing the user interface screen to be displayed on a display.
Abstract: A current Java project is converted to a Maven project, by scanning the the current Java project to identify a structure of the Java project, generating a project template for the Maven project based on the identified structure of the Java project, arranging files associated with the Java project according to a structure of the project template generated for the Maven project, validating dependencies and linkages associated with a plurality of modules of the current Java project based on corresponding module requirements, generating a Project Object Model (POM) file for each of the modules, generating a root POM file for the Maven project that includes the dependencies, executing a build of the Maven project utilizing the POM files and the root POM file to generate artifacts for the Maven project, and deploying the artifacts in a central repository and a testing environment.
Abstract: A system, method, and computer program product are provided for managing services for a service provider at a device within proximity to a location of the service provider, utilizing logic of a centralized environment. In use, at least one real-time service managed for a service provider by a centralized environment is identified. Furthermore, logic of the centralized environment for the management of the at least one real-time service is deployed to at least one device within a predetermined proximity to a location of the service provider.
Type:
Grant
Filed:
November 17, 2014
Date of Patent:
October 9, 2018
Assignees:
Amdocs Development Limited, Amdocs Software Systems Limited